Table 1.
Characteristics of patients and outcomes of included trials
| Trial name | Arm | N | Median age | Males (%) | Smoke (%) | ECOG1 (%) | Brain metastases (%) | ORR (%) | Follow-up (m) | OS (m) | PFS (m) | HR for PFS 95%CI | HR for OS 95%CI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMpower133 | Atezolizumab + chemotherapy | 201 | 64 | 64.2 | 95.5 | 63.7 | 8.5 | 60 | 22.9 | 12.3 | 5.2 | 0.77 (0.63–0.95) | 0.76 (0.60–0.95) |
| chemotherapy | 202 | 64 | 65.3 | 98.5 | 66.8 | 8.9 | 64 | 22.9 | 10.3 | 4.3 | Ref | Ref | |
| CASPIAN | Durvalumab + chemotherapy | 268 | 62 | 71 | 92 | 63 | 10 | 68 | 25.1 | 12.9 | 5.1 | 0.80 (0.66–0.96) | 0.75 (0.62–0.91) |
| chemotherapy | 269 | 63 | 68 | 94 | 67 | 10 | 58 | 25.1 | 10.5 | 5.4 | Ref | Ref | |
| KEYNOTE-604 | Pembrolizumab + chemotherapy | 228 | 64 | 66.7 | 96.5 | 73.7 | 14.5 | 71 | 10.8 | 4.5 | 0.75 (0.61–0.91) | 0.80 (0.64–0.98) | |
| chemotherapy | 225 | 65 | 63.1 | 96.4 | 75.1 | 9.8 | 62 | 9.7 | 4.3 | Ref | Ref | ||
| EA5161 | Nivolumab + chemotherapy | 80 | 52 | 11.3 | 5.5 | 0.65 (0.46–0.91) | 0.67 (0.46–0.98) | ||||||
| chemotherapy | 80 | 48 | 8.5 | 4.6 | Ref | Ref |
N Number; ECOG Eastern Cooperative Oncology Group; ORR Objective response rate; HR Hazard ratio; PFS Progression-free survival; OS Overall survival; Ref: Reference